Background {#Sec1}
==========

Gastric cancer is the fifth most common cancer worldwide and ranks third cause of cancer related mortality \[[@CR1]\]. Almost over half of new diagnosed cases are from eastern Asian, predominantly in China \[[@CR2]\]. Gastric cancer is a multifactorial disease with multistep etiology. Epidemiological studies have demonstrated that interaction of environmental factors, such as *Helicobacter pylori* (*H. pylori*) infection, excessive salt intake, alcohol drinking and tobacco smoking, and genetic background was regarded as risk of gastric cancer.

For environmental factors, *H. pylori* causing chronic inflammation has been verified as a key factor involved in gastric carcinogenesis. Moreover, for genetic background, polymorphisms in immune-related genes, such as *IL*-*1B*, *IL*-*1RN*, *IL*-*10*, could affect their expression and were suggested as risk factors of gastric cancer \[[@CR3], [@CR4]\]. In addition, we previously reported genetic polymorphisms in the promoter of *IL*-*1B/IL*-*1RN* were the risk of gastric cancer \[[@CR5], [@CR6]\]. Of immune-related genes, IL-16 is a pro-inflammatory cytokine that has a variety of biological functions, playing role in the development and homeostasis of the immune system \[[@CR7]\], and stimulating the secretion of tumor-associated inflammatory cytokines including TNF-α, IL-1β, IL-6, and IL-15 \[[@CR8]\]. In addition, polymorphisms in *IL*-*16* were investigated to be risk of various cancers, including gastric cancer, and the diagnostic and prognostic value of serum IL-16 levels for patients with gastric cancer was also reported \[[@CR9]\]. Transforming growth factor beta-1 (TGF-β1), a multifunctional cytokine, combined it's receptor (*TGFBR1*) plays biphasic role in carcinogenesis that, in early stages of cancer, it acts as a tumor suppressor by inhibiting cellular proliferation or by promoting cellular differentiation and apoptosis; in later stages of cancer, however, it turns to be a tumor promoter by stimulating angiogenesis and cell motility, suppressing immune response, and increasing progressive invasion and metastasis \[[@CR10]--[@CR12]\]. Moreover, serum TGF-β1 levels implicating a predictive and prognostic value for patients with gastric cancer \[[@CR13], [@CR14]\] may indicate polymorphisms in genes of TGF-β1 pathway including TGFBR1 could influence the risk and clinical progression of gastric cancer \[[@CR15]--[@CR17]\]. In the progression of *H. pylori* infection, toll-like receptors (TLRs), a group of membrane-bound receptors proteins, play a pivotal role in innate immune response and provide first line of host defense. Among TLRs, TLR-4 is the main receptor of lipopolysaccharide (LPS) and plays a role in initiating the inflammatory response of *H. pylori* infection. After binding of microbial ligands, a dysregulation of TLR signalling may contribute to an unbalanced ratio between pro- and anti-inflammatory cytokines, resulting in increasing higher risk of developing gastric cancer \[[@CR18]\]. Similarly, polymorphisms in *TLR4* has been implicated as risk factors for gastric cancer \[[@CR18]\]; however, the conclusion of susceptibility of these polymorphisms to gastric cancer risk remains elusive \[[@CR19]--[@CR21]\].

Immune response triggered by *H. pylori* infection, including host adaptive immune response (such as IL-1b, TNF-a, IL-10, IL-16) and innate immune response (such as TLR4), is an intricate progression, which is responsible for clinical outcomes of individuals with *H. pylori* infection. Thus, polymorphisms occurring in immune genes could serves as possible susceptibility factors to the development of gastric cancer and have a predictive value for gastric cancer clinical outcome. Here, we conducted a case--control study to assess the susceptibility of polymorphisms in *IL*-*16*, *TGFBR1* and *TLR4* to risk of gastric cancer in a Chinese population, and the prognostic value of the polymorphisms was also evaluated by a retrospective study.

Materials and methods {#Sec2}
=====================

Study population {#Sec3}
----------------

For the case--controls study, we recruited 479 patents histologically diagnosed as gastric cancer and 483 age- and sex-matched healthy controls who came to the hospital for routine physical examination. The demographic features of participants were collected via a questionnaire or by reviewing patients' medical records. The TNM stages were classified according to American Joint Commission for Cancer Staging in 2002 (the sixth edition). For retrospective study, we traced survival state of all patients through on-site interview, direct calling or medical chart review, and finally, a total of 460 patients were followed up to 5 years. The protocol of this study was approved by the Institutional Review Board of the Nanjing First Hospital, and written informed consents were obtained from all participants.

DNA extraction and genotyping {#Sec4}
-----------------------------

We retrieved the potential genetic variations in *IL*-*16*, *TGF*-*BR1* and *TLR4* from the National Center for Biotechnology Information dbSNP database (<http://www.ncbi.nlm.nih.gov/projects/SNP>), and then the genetic variations were selected followed the following criteria: (1) the minor allele frequency (MAF) is not less than 5% in Han Chinese population; (2) with position in exons, promoter region, 5′ untranslated regions (UTR) or 3′ UTR; and (3) published results shown to be associated with any cancer risk. For those polymorphisms in intron if meet the criterion (3) were also included. Finally, a total of 11 polymorphisms were selected (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

The DNA extraction and genotyping was performed as we previously described \[[@CR22]\]. A GoldMag-Mini Whole Blood Genomic DNA Purification Kit (GoldMag Co. Ltd. Xi'an, China) was used for DNA extraction, and then the genotyping was performed on the SequenomMassARRAY platform.

*H. pylori* infection detection {#Sec5}
-------------------------------

To identify the *H. pylori* infection, the serum of all participants were collected to detect *H. pylori* antibody by using a *H. pylori* immunogold testing kit (KangmeiTianhong Biotech Co., Ltd, Beijing, China).

### Statistical analysis {#Sec6}

The difference of demographic features of the two groups was assessed by *t* test or χ^2^ test. For the distribution of genotypes, a goodness of fit Chi square test was adopted to test the Hardy--Weinberg equilibrium (HWE) in the control group, and then, the susceptibility of polymorphisms to gastric cancer risk was expressed with odds ratios (ORs) and 95% confidence intervals (CIs). Subgroups analyze was conducted if there was a significant association of the polymorphism to gastric cancer risk. The risk of polymorphisms was calculated by using a logistic regression model based on SAS v9.1 (SAS Institute, Cary, NC, USA). The hazard ratios (HRs) of genotypes to survival time of patients were calculated by Cox regression analysis with SPSS 11.0 (SPSS, Chicago, IL, USA). The p value \< 0.05 was considered statistically significant difference.

Result {#Sec7}
======

Characteristics of the study population {#Sec8}
---------------------------------------

The health controls and patients were matched for age (p = 0.748) and gender (p = 0.881). There were significant differences between the two groups with respect to the frequency of *H. pylori* infection (p = 0.039), cigarette smoking (p \< 0.001) and alcohol consumption (p \< 0.001), summarized in Additional file [1](#MOESM1){ref-type="media"}: Table S2. The observed frequencies of all tested genotypes in controls did not deviate from HWE (shown in Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Association between polymorphisms and risk of gastric cancer {#Sec9}
------------------------------------------------------------

Two polymorphisms in *TGFBR1* were observed to be potentially associated with risk of gastric cancer. rs10512263 CC genotype was found to be a decreased risk of gastric cancer (CC vs. TT: adjusted OR = 0.54, 95% CI 0.31--0.97, p = 0.039); however, rs334348 GG genotype was associated with increased risk of gastric cancer (GG vs. AA: adjusted OR = 1.51, 95% CI 1.05--2.18, p = 0.028), shown in Table [1](#Tab1){ref-type="table"}.Table 1Association between polymorphisms and risk of gastric cancerPolymorphismGenotypeCases, n (%)Controls, n (%)OR (95% CI)OR (95% CI)^a^*p* value*IL*-*16* rs4072111CC334 (69.73)345 (71.43)ReferenceReferenceTC126 (26.30)122 (25.26)1.07 (0.80,1.43)1.01 (0.75,1.36)0.970TT19 (3.97)16 (3.31)1.23 (0.62,2.43)1.20 (0.60,2.41)0.600TC/TT145 (30.27)138 (28.57)1.09 (0.82,1.43)1.02 (0.77,1.36)0.870Additive model1.08 (0.86,1.37)1.04 (0.82,1.32)0.755rs4778889TT267 (55.74)266 (55.07)ReferenceReferenceCT182 (38.00)192 (39.75)0.94 (0.73,1.23)0.92 (0.70,1.20)0.524CC30 (6.26)25 (5.18)1.20 (0.68,2.09)1.19 (0.68,2.10)0.542CT/CC212 (44.26)217 (44.93)0.97 (0.76,1.26)0.95 (0.73,0.23)0.688Additive model1.01 (0.82,1.25)1.00 (0.81,1.23)0.965rs859TT129 (26.93)124 (25.67)ReferenceReferenceCT235 (49.06)248 (51.35)0.91 (0.67,1.24)0.88 (0.64,1.20)0.406CC115 (24.01)111 (22.98)1.00 (0.70,1.43)0.98 (0.68,1.41)0.899CT/CC350 (73.07)359 (74.33)0.94 (0.70,1.25)0.92 (0.68,1.23)0.551Additive model1.00 (0.83,1.19)0.98 (0.82,1.18)0.859rs11556218TT306 (63.88)308 (63.77)ReferenceReferenceGT151 (31.52)157 (32.51)1.97 (0.74,1.27)0.93 (0.71,1.23)0.628GG22 (4.59)18 (3.73)1.23 (0.65,2.34)1.29 (0.68,2.48)0.439GT/GG173 (36.12)175 (36.23)1.00 (0.77,1.29)0.97 (0.94,1.27)0.820Additive model1.02 (0.82,1.28)1.01 (0.81,1.27)0.913rs1131445TT221 (46.14)210 (43.48)ReferenceReferenceCT211 (44.05)222 (45.96)0.90 (0.69,1.18)0.94 (0.72,1.23)0.655CC47 (9.81)51 (10.56)0.88 (0.57,1.36)0.93 (0.59,1.46)0.748CT/CC258 (53.86)273 (56.52)0.90 (0.70,1.16)0.93 (0.72,1.21)0.592Additive model0.92 (0.76,1.12)0.95 (0.78,1.16)0.618*TLR4* rs10759932TT240 (50.10)251 (51.97)ReferenceReferenceTC191 (39.87)196 (40.58)1.02 (0.78,1.33)1.05 (0.80,1.38)0.733CC48 (10.02)36 (7.45)1.39 (0.87,2.22)1.38 (0.86,2.23)0.184TC/CC239 (49.90)232 (48.03)1.08 (0.84,1.39)1.10 (0.85,1.42)0.481Additive model1.11 (0.91,1.35)1.12 (0.92,1.36)0.275rs1927911GG171 (35.70)175 (36.23)ReferenceReferenceGA226 (47.18)226 (46.79)1.02 (0.77,1.35)1.04 (0.78,1.38)0.801AA82 (17.12)82 (16.98)1.02 (0.71,1.48)0.99 (0.68,1.45)0.967GA/AA308 (64.30)308 (63.77)1.02 (0.79,1.33)1.03 (0.79,1.34)0.844Additive model1.01 (0.85,1.21)1.01 (0.84,1.21)0.930rs11536889GG303 (63.26)293 (60.66)ReferenceReferenceCG156 (32.57)166 (34.37)0.91 (0.69,1.19)0.91 (0.69,1.19)0.477CC20 (4.18)24 (4.97)0.81 (0.44,1.49)0.76 (0.40,1.43)0.392CG/CC176 (36.74)190 (39.34)0.90 (0.69,1.16)0.89 (0.69,1.16)0.402Additive model0.90 (0.73,1.13)0.90 (0.72,1.12)0.355*TGF*-*BR1* rs6478974TT219 (45.72)194 (40.17)ReferenceReferenceAT204 (42.59)220 (45.55)0.82 (0.63,1.08)0.80 (0.61,1.06)0.118AA56 (11.69)69 (14.29)0.72 (0.48,1.08)0.68 (0.45,1.02)0.063AT/AA260 (54.28)289 (59.83)0.80 (0.62,1.03)0.78 (0.60,1.01)0.055Additive model0.84 (0.70,1.01)*0.82 (0.68,0.99)0.038*rs334348AA143 (29.85)158 (32.71)ReferenceReferenceAG221 (46.14)240 (49.69)1.02 (0.76,1.36)1.05 (0.78,1.42)0.730GG115 (24.01)85 (17.60)1.50 (1.04,2.14)*1.51 (1.05,2.18)0.028*AG/GG336 (70.15)325 (69.29)1.14 (0.87,1.50)1.17 (0.89,1.55)0.263Additive model1.20 (1.01,1.43)*1.22 (1.02,1.46)0.032*rs10512263TT279 (58.25)262 (54.24)ReferenceReferenceCT178 (37.16)187 (38.72)0.89 (0.69,1.17)0.87 (0.66,1.14)0.297CC22 (4.59)34 (7.04)0.61 (0.35,1.07)*0.54 (0.31,0.97)0.039*CT/CC200 (41.75)221 (45.76)0.85 (0.66,1.10)0.82 (0.63,1.06)0.127Additive model0.84 (0.68,1.03)*0.81 (0.65,1.00)0.047*Italic represents any values with p \< 0.05*OR* odds ratio^a^Adjusted for age, gender, smoking, drinking, and *H. pylori* infection status

Stratified analysis by age, gender, *H. pylori* infection status, tumor stage and tumor site revealed that the significant association of rs10512263 to risk of gastric cancer was maintained in the subgroup of male, and subgroup of individuals with older age, shown in Table [2](#Tab2){ref-type="table"}. In the stratification analysis by pathologic characteristics, we observed that the significant association of rs334348 to risk of gastric cancer was maintained in the subgroup of patients with clinical stage T1--T2. In addition, although no significant association was found, aboundary significant of two polymorphisms to risk of gastric cancer was observed in subgroup of clinical stage T1--T2 and in subgroup of non-cardiac, shown in Table [3](#Tab3){ref-type="table"}.Table 2Stratification analyses the association between polymorphisms in *TGF*-*BR1* and gastric cancer riskGenotypeAgeGender*H. pylori* infection≤ 64\> 64MaleFemalePositiveNegativeCa/CoOR (95% CI)^a^*p* valueCa/CoOR (95% CI)^a^*p* valueCa/CoOR (95% CI)^a^*p* valueCa/CoOR (95% CI)^a^*p* valueCa/CoOR (95% CI)^a^*p* valueCa/CoOR (95% CI)^a^*p* valuers6478974 TT100/87Reference119/107Reference156/134Reference63/60Reference120/91Reference99/103Reference AT101/1130.76 (0.51,1.13)0.175103/1070.85 (0.58,1.25)0.412159/1700.80 (0.58,1.10)0.16445/500.81 (0.46,.41)0.452108/1070.76 (0.52,1.12)0.16096/1130.86 (0.58,1.28)0.457 AA28/300.76 (0.41,1.40)0.37428/390.61 (0.34,1.07)0.08238/54*0.55 (0.33,0.90)0.017*18/151.19 (0.55,2.58)0.66333/330.73 (0.41,1.28)0.27223/360.62 (0.34,1.14)0.127 AT/AA129/1430.76 (0.52,1.11)0.156131/1460.80 (0.56,1.14)0.206197/224*0.74 (0.54,1.00)0.049*63/650.89 (0.54,1.48)0.658141/1400.75 (0.52,1.08)0.125119/1490.81 (0.55,1.17)0.260 Additive model0.83 (0.63,1.10)0.1990.81 (0.62,1.04)0.100*0.76 (0.61,0.95)0.016*1.01 (0.70,1.44)0.9750.83 (0.64,1.08)0.1570.81 (0.62,1.07)0.135rs334348 AA72/74Reference71/84Reference108/121Reference35/37Reference77/83Reference66/75Reference AG105/1220.95 (0.62,1.47)0.832116/1181.16 (0.77,1.76)0.478168/1731.15 (0.81,1.62)0.14353/670.85 (0.46,1.54)0.583124/1001.43 (0.94,2.17)0.09397/1400.79 (0.51,1.21)0.278 GG52/341.57 (0.90,2.73)0.11463/511.44 (0.88,2.37)0.14677/641.37 (0.89,2.11)0.14938/211.97 (0.94,4.11)0.07260/480.37 (0.83,2.25)0.22355/371.71 (0.99,2.53)0.054 AG/GG157/1561.09 (0.72,1.63)0.694179/1691.26 (0.86,1.85)0.245245/2371.20 (0.87,1.66)0.26991/881.10 (0.63,1.92)0.745184/1481.40 (0.95,2.06)0.088152/1770.98 (0.66,1.47)0.927 Additive model1.21 (0.93,1.59)0.1611.22 (0.95,1.56)0.1131.17 (0.95,1.45)0.1411.36 (0.95,1.94)0.0961.19 (0.93,1.53)0.1661.25 (0.96,1.64)0.097rs10512263 TT130/129Reference149/133Reference202/189Reference77/73Reference150/127Reference129/135Reference CT88/880.95 (0.64,1.41)0.81490/990.80 (0.55,1.16)0.230136/1400.89 (0.65,1.22)0.47042/470.82 (0.48,1.41)0.47198/870.91 (0.62,1.33)0.61080/1000.83 (0.56,1.22)0.335 CC11/130.70 (0.29,1.67)0.41711/21*0.44 (0.20,0.96)0.040*15/29*0.41 (0.21,0.81)0.010*7/51.40 (0.42,4.63)0.58513/170.64 (0.29,1.39)0.2589/170.45 (0.19,1.10)0.080 CT/CC99/1010.91 (0.62,1.33)0.621101/1200.74 (0.52,1.06)0.101151/1690.80 (0.59,1.09)0.15949/520.87 (0.52,1.46)0.604111/1040.86 (0.60,1.23)0.40589/1170.77 (0.53,1.13)0.180 Additive model0.88 (0.64,1.21)0.441*0.74 (0.55,0.99)0.0400.76 (0.60,0.98)0.033*0.96 (0.63,1.48)0.8640.85 (0.63,1.14)0.2720.76 (0.56,1.04)0.083Italic represents any values with p \< 0.05*OR* odds ratio, *Ca* case, *Co* control^a^Adjusted for age, gender, smoking, drinking, and *H. pylori* infection status Table 3Stratification analyses the association between polymorphisms in *TGF*-*BR1* and gastric cancer by pathologic characteristicsGenotypeCoClinical stageTumor siteT1--T2T3--T4CardiacNon-cardiacCaOR (95% CI)^a^*p* valueCaOR (95% CI)^a^*p* valueCaOR (95% CI)^a^*p* valueCaOR (95% CI)^a^*p* valuers6478974 TT19475Reference144Reference62Reference157Reference AT220690.82 (0.55,1.21)0.3111350.79 (0.58,1.08)0.140620.87 (0.58,1.31)0.4971420.78 (0.57,1.05)0.105 AA69150.54 (0.28,1.04)0.065410.76 (0.49,1.20)0.238140.61 (0.32,1.17)0.139420.72 (0.45,1.13)0.147 AT/AA289840.75 (0.52,1.09)0.1341760.79 (0.59,1.05)0.109760.80 (0.54,1.18)0.2681840.77 (0.58,1.02)0.069 Additive model0.76 (0.57,1.01)0.0540.85 (0.69,1.05)0.1400.80 (0.60,1.07)0.1350.83 (0.67,1.02)0.077rs334348 AA15845Reference98Reference40Reference103Reference AG240731.19 (0.76,1.87)0.4421481.01 (0.73,1.41)0.937641.14 (0.73,1.80)0.5651571.04 (0.75,1.45)0.825 GG8541*1.73 (1.03,2.90)0.039*741.42 (0.94,2.13)0.092341.56 (0.91,2.68)0.103811.48 (0.99,2.21)0.055 AG/GG3251141.31 (0.87,1.99)0.1962221.12 (0.82,1.52)0.4871.24 (0.81,1.89)0.3231.15 (0.85,1.57)0.373 Additive model*1.33 (1.02,1.73)0.035*1.17 (0.96,1.43)0.1251.25 (0.95,1.64)0.1081.21 (0.99,1.47)0.069rs10512263 TT26299Reference180Reference82Reference197Reference CT187530.75 (0.51,1.12)0.1611250.93 (0.69,1.25)0.620500.81 (0.54,1.21)0.3001280.90 (0.67,1.21)0.479 CC3470.51 (0.21,1.24)0.137150.59 (0.31,1.13)0.11360.51 (0.20,1.28)0.149160.56 (0.29,1.07)0.080 CT/CC221600.71 (0.49,1.05)0.0841400.88 (0.66,1.17)0.366560.76 (0.51,1.12)0.1621440.85 (0.64,1.13)0.256 Additive model0.73 (0.53,1.01)0.0540.85 (0.67,1.08)0.1840.76 (0.55,1.05)0.0930.83 (0.66,1.05)0.120Italic represents any values with p \< 0.05*OR* odds ratio, *Ca* case, *Co* control^a^Adjusted for age, gender, smoking, drinking, and *H. pylori* infection status

### Association between polymorphisms and clinical outcome {#Sec10}

A retrospective study was conducted based on 460 patients with follow-up information on survival period of 5 years. We found that carriers harboring rs1927911 A allele (GA/AA) or rs10512263 C allele (CT/CC) have unfavorable survival time than none carriers (rs1927911: GA/AA vs. GG: adjusted HR = 1.27, 95% CI 1.00--1.63, p = 0.054; rs10512263: CT/CC vs. TT: adjusted HR = 1.29, 95% CI 1.02--1.63, p = 0.031), shown in Table [4](#Tab4){ref-type="table"}.Table 4Association between polymorphism and overall survival of gastric cancer patients in co-dominant modelGenotypeCases, nDeath, n (%)Log-rank p-valueHRHR (95% CI)^a^p-valuers4072111 CC322205 (0.64)ReferenceReference TC/TT13881 (0.59)0.3440.88 (0.68,1.14)1.12 (0.86,1.45)0.408rs4778889 TT256172 (0.67)ReferenceReference CT/CC204114 (0.56)0.0280.77 (0.61,0.97)0.84 (0.66,1.06)0.146rs11556218 TT293192 (0.66)ReferenceReference GT/GG16794 (0.56)0.1100.82 (0.64,1.05)0.94 (0.73,1.20)0.607rs859 AA10968 (0.62)ReferenceReference GA/GG351218 (0.62)0.6331.07 (0.81,1.40)1.03 (0.79,1.36)0.814rs1131445 TT211127 (0.60)ReferenceReference CT/CC249159 (0.64)0.1501.18 (0.94,1.50)1.06 (0.84,1.35)0.617rs10759932 TT231141 (0.61)ReferenceReference TC/CC229145 (0.63)0.5631.07 (0.85,1.35)1.07 (0.84,1.35)0.588rs1927911 GG16595 (0.58)ReferenceReference GA/AA295191 (0.65)0.1131.22 (0.95,1.56)*1.27 (1.00,1.63)*0.054rs11536889 GG293181 (0.62)ReferenceReference CG/CC167105 (0.63)0.9571.01 (0.79,1.28)0.99 (0.77,1.26)0.924rs6478974 TT212126 (0.59)ReferenceReference TA/AA248160 (0.65)0.2241.16 (0.92,1.46)1.23 (0.98,1.56)0.079rs334348 GG11064 (0.58)ReferenceReference AG/AA350222 (0.63)0.4911.10 (0.84,1.46)1.04 (0.79,1.38)0.787rs10512263 TT269157 (0.58)ReferenceReference CT/CC191129 (0.68)0.031*1.29 (1.02,1.63)1.29 (1.02,1.63)0.031*Italic represents any values with p \< 0.05^a^Adjusted for age, sex, tumor site and TNM stage

The stratified analysis based on the age, gender, tumor site or clinical stage was also performed for the significant polymorphisms, and the result revealed that carriers with rs1927911 A allele have poor survival in subgroup of patients with age younger than 64 years old (GA/AA vs. GG: adjusted HR = 1.64, 95% CI 1.13--2.38), male (GA/AA vs. GG: adjusted HR = 1.36, 95% CI 1.03--1.81), and non-cardiac gastric cancer (GA/AA vs. GG: adjusted HR = 1.34, 95% CI 1.00--1.80), and that rs1927911 A allele carriers have poor survival in the subgroup of male (CT/CC vs. TT: adjusted HR = 1.43, 95% CI 1.09--1.87), patients in clinical stage T1--T2 (CT/CC vs. TT: adjusted HR = 2.54, 95% CI 1.38--4.69), and non-cardiac gastric cancer (NCGC) (CT/CC vs. TT: adjusted HR = 1.36, 95% CI 1.02--1.80), shown in Table [5](#Tab5){ref-type="table"}.Table 5Subgroup analyses of association between polymorphisms and survival in co-dominant modelGroupCase, nDeath, n (%)rs1927911rs10512263GA/AA: GGHR (95% CI)^a^p-valueCT/CC: TTHR (95% CI)^a^P-valueAge \< 64224130 (0.58)*142/821.64 (1.13,2.38)0.009*97/1271.34 (0.95,1.90)0.099 ≥ 64236156 (0.66)153/831.04 (0.75,1.45)0.81794/1421.19 (0.86,1.64)0.286Gender Male338214 (0.63)*216/1221.36 (1.03,1.81)0.033145/1931.43 (1.09,1.87)0.010* Female12272 (0.64)79/431.08 (0.65,1.80)0.75446/761.26 (0.76,2.08)0.365Clinical stage T1--T215942 (0.26)102/571.36 (0.70,2.66)0.367*60/992.61 (1.40,4.86)0.003* T3--T4301244 (0.81)193/1081.21 (0.93,1.58)0.160131/1701.04 (0.80,1.34)0.784Tumor site Cardiac13287 (0.66)91/411.07 (0.67,1.71)0.76854/781.47 (0.94,2.31)0.094 Non-cardiac328199 (0.61)*204/1241.34 (1.00,1.80)0.050137/1911.36 (1.02,1.80)0.034*Italic represents any values with p \< 0.05^a^Adjusted for age, sex, tumor site and TNM stage

To identify the impact of the co-occurrence of rs1927911 and rs10512263 on overall survival, we analyzed the association between locus--locus interaction and overall survival, and the result shown that individuals harboring both two minor alleles (rs1927911GA/AA and rs10512263CT/CC) suffered a significant unfavorable survival (adjusted HR = 1.64, 95% CI 1.17--2.31), shown in Table [6](#Tab6){ref-type="table"}.Table 6Locus--locus interactions between rs1927911 and rs10512263 and survivalrs1927911rs10512263Cases, nDeath, n (%)Log-rank p valueHR (95% CI)^a^p-valueGGTT10053 (53.00)0.018ReferenceGGCT/CC6542 (64.42)1.18 (0.79,1.03)0.421GA/AATT169104 (61.54)1.20 (0.86,1.67)0.279GA/AACT/CC12687 (69.05)*1.64 (1.17,2.31)0.005*Italic represents any values with p \< 0.05^a^Adjusted for age, sex, tumor site and TNM stage

Discussion {#Sec11}
==========

This case--control study combined retrospective study observed that two polymorphisms (rs334348, rs10512263) in *TGFBR1* were associated with risk of gastric cancer, and that rs1927911and rs10512263 were associated with survival of gastric cancer patients.

*TGFBR1* rs6478974 is a genetic variation in intron 1, it was previously reported to be associated with microRNAs expression and involved in carcinogenesis \[[@CR23]\]. In addition, the significant association of rs6478974 to gastric cancer risk was also reported \[[@CR15]\]; however, in this study, we observed such a significant association in the subgroup of male but for all participants, indicating male carrying rs6478974 polymorphisms have higher gastric cancer risk than female. Another polymorphism rs10512263 locating intron 1 of *TGBR1* was observed as a susceptibility of gastric cancer in this study; however, an opposite result was also reported \[[@CR15]\]. It is noted that, in the subgroup analysis, we observed that the decreased risk of the polymorphism to gastric cancer was maintained in the subgroup of male, and those with age older than 64 years, suggesting the susceptibility of the polymorphism to gastric cancer risk could be effected by demographic characteristics of participants. Due to the limited sample sized of this study, the significant should be verified by further study. *TGFBR1* rs334348 located in the 3′ UTR region, and it was suggested with location in miRNA-628-5p binding site, resulting in GG genotype turn to be associated with lower *TGFBR1* expression \[[@CR24]\]. In addition, previous study has also reported that it could confer an increased risk of colorectal cancer by affecting *TGFBR1* expression \[[@CR25]\].

In the retrospective study, we observed *TLR4* rs1927911 and *TGFBR1* rs10512263 were associated with clinical outcomes of gastric cancer patients. *TLR4* rs1927911 is an intron variation that was previously reported as a protective factor for gastric cancer \[[@CR26], [@CR27]\]; however, we failed to find such a significant association but we observed it was associated with unfavorable OS of gastric cancer patients, especially for male, patients with age younger than 64 years old, or patients with NCGC. To date, the function of rs1927911 remains unclear, we speculated that such a significant association was related the microenvironment of cancer by that TLR4 signaling was involved in drug resistant by inducing the M1 phenotype macrophages \[[@CR28]\] and by that TLR4/NF-κB signal pathway mediated uncontrolled inflammation \[[@CR29]\]. Moreover, this study observed *TGFBR1* rs10512263 has a predictive value for clinical outcomes of gastric cancer patients. Although the function of rs10512263 remains unclear, TGF-β signaling has been suggested to promote gastric cancer progression by enhancing motility and inducing invasiveness of gastric cancer cell \[[@CR11]\], or by promoting tumor vasculature conformation \[[@CR30]\], which could be partly explained for the predictive role of *TGFBR1* rs10512263 in gastric cancer patients.

Polymorphisms in three immune related genes was discussed for their susceptibility and predictive role in gastric cancer. Here, some limitations of this study should be noted. Firstly, the function of these polymorphisms is largely unclear, and we failed to assess the association of polymorphism and TGFBR1, TLR4 expression in patients. Instead of that, to perform functional candidate polymorphism and expression quantitative trait locus (eQTL) analyses on the promising genes, we mined the data from the following databases: GTExPortal (<https://www.gtexportal.org/home/>) and Haploreg (<http://www.broadinstitute.org/mammals/haploreg/haploreg.php>), and the results shown that *TLR4* rs1927911, *TGF*-*BR1* rs6478974 and rs334348 could affect their corresponding gene expression, and that *TGF*-*BR1* rs10512263 could regulate certain motifs, which were consistent to our results, see Additional file [2](#MOESM2){ref-type="media"}: Figures S1 and S2. Secondly, the sample size of this study was not large enough, which may weaken the statistical power. Thirdly, environmental factors, such as diet, physical exercises, gastric diseases history, and subtype of *H. pylori* were not included in this study, which may influence the conclusion. Finally, there are number of polymorphisms in the immune related genes, here we selected three of them and some more immune related genes required to be discussed.

Conclusion {#Sec12}
==========

We concluded that two polymorphisms (rs334348, rs10512263) in *TGF*-*BR1* were associated with risk of gastric cancer, and that *TLR4* rs1927911 and *TGFBR1* rs10512263 were associated with clinical outcomes of gastric cancer patients. This is a study firstly discussed the relation of polymorphisms in genes of *IL*-*16*, *TGFBR1* and *TLR4* pathways and survival time of gastric cancer patients in Chinese population and our study could provide epidemiology data for further study.

Additional files
================

 {#Sec13}

**Additional file 1: Table S1.** Information of enrolled genetic variations. **Table S2.** Clinical and demographic characteristics of enrolled participants. **Additional file 2: Figure S1.** eQTL analysis of mRNA expression in whole blood and genotype data. A: *TLR4* rs1927911, p-value = 0.000016; B: *TGF-BR1* rs6478974, p-value = 6.5e-7, and C: rs334348, p-value = 0.0000029. **Figure S2.** Results from the Haploreg website for the *TGF-BR1* rs10512263.
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